Rare diseases
Investigational molecules
Locations
Recruiting trials first
4 clinical trials in this condition
Belgium
Ireland
AustriaBelgiumIn short
Three clinical trials are currently recruiting patients with endometrial adenocarcinoma, testing new investigational treatments including antibody-drug conjugates and targeted therapies. These studies are being conducted across multiple European countries including Belgium, Spain, and several other nations, offering opportunities for patients whose cancer has advanced or spread beyond the original site.
This trial is testing a new medication called JK06, an antibody-drug conjugate designed to target and attack cancer cells. The medication is delivered directly into the bloodstream through an intravenous infusion every three weeks. The study is designed to help researchers understand how safe this treatment is and to determine the best dose for future studies.
Who can participate: The trial is open to adults aged 18 and older who have advanced or metastatic cancer that cannot be surgically removed, including endometrial adenocarcinoma. Patients must have tried standard treatments already or be unable to receive them. They need to be reasonably active (able to carry out light work even if restricted in strenuous activities) and have a life expectancy of at least 12 weeks. The cancer must be measurable on imaging tests, and patients must have adequate blood counts and organ function. Women who can become pregnant must use two forms of effective birth control, and men with partners who can become pregnant must use barrier contraception.
Who cannot participate: Patients who have recently received other cancer treatments, have certain other health conditions that could interfere with the study, are pregnant or breastfeeding, have allergies to the study medication, cannot follow study procedures, are in another clinical trial, have uncontrolled heart conditions, active infections, serious illnesses, recent or planned surgery, or a history of substance abuse may not be eligible.
Study focus: The main goal is to evaluate the safety and tolerability of JK06 while finding the optimal dose. The study is divided into two phases: a dose escalation phase where the amount of medication is gradually increased, and a dose expansion phase where more patients receive the selected dose to further evaluate its effects. Patients will be monitored closely throughout the treatment for any side effects or changes in their condition.
This study focuses on testing bemarituzumab, a targeted therapy that works by binding to a specific protein called FGFR2b found on certain cancer cells. The medication is given through regular intravenous infusions. This trial includes patients with endometrial adenocarcinoma among several other solid tumor types.
Who can participate: Adults aged 18 and older who have confirmed diagnoses of endometrial cancer that has returned or not responded to at least one previous treatment. The tumor must show high levels of FGFR2b protein through special laboratory testing and must be measurable using standard imaging techniques. Patients need adequate blood cell counts, liver function, kidney function, and normal blood clotting function. They should have a confirmed diagnosis through tissue examination and meet specific requirements regarding prior treatments.
Who cannot participate: Patients with a history of severe allergic reactions, active or untreated brain metastases, significant heart problems (including unstable heart disease, recent heart attack, or uncontrolled high blood pressure), active uncontrolled infections, another cancer diagnosis within the past three years, pregnancy or breastfeeding, major surgery within four weeks, participation in another clinical trial within four weeks, serious medical conditions that could interfere with participation, known HIV, active hepatitis B or C, history of organ transplantation, or current use of medications that could interact with the study drug are not eligible.
Study focus: The trial aims to test how safe bemarituzumab is and how well it works in treating solid tumors with FGFR2b overexpression. The study is divided into two parts: the first closely monitors patient responses and side effects, while the second evaluates how effective the medication is at fighting cancer. Throughout the study, doctors will track progress using medical tests and imaging scans such as CT or MRI to monitor how tumors respond to treatment. The study is expected to continue until September 2026.
This trial is testing JK08, an experimental IL-15 antibody fusion protein that targets CTLA-4, designed to stimulate the immune system against cancer. The study explores using JK08 alone and in combination with pembrolizumab (Keytruda) and lenvatinib (Lenvima). JK08 is administered as an injection under the skin, while pembrolizumab is given through infusion and lenvatinib is taken orally as capsules.
Who can participate: Adults aged 18 and older with advanced or metastatic cancer that cannot be surgically removed, including endometrial cancer. Patients must have tried standard treatments without success or cannot have them for medical reasons. They need to be fully active or restricted only in physically strenuous activity but able to carry out light work, with a life expectancy of at least 12 weeks. The disease must be measurable on imaging tests like CT or MRI, and patients must have acceptable lab results including certain levels of blood components. Both men and women must use effective birth control methods during the study and for 90 days afterward.
Who cannot participate: The trial does not specify detailed exclusion criteria in the provided information, but standard cancer trial exclusions typically apply regarding serious health conditions that could interfere with study participation, active uncontrolled infections, and certain other medical complications.
Study focus: The primary purpose is to understand the safety and tolerability of JK08 and to determine the best dose for patients. The study begins with a dose escalation phase to find the maximum tolerable dose, then expands to include more patients to further evaluate the optimal dose. As an immunotherapy agent, JK08 is designed to boost the immune response against cancer cells by targeting CTLA-4, a protein involved in regulating the immune system. The study is expected to conclude by February 2026.
Three clinical trials are currently available for patients with endometrial adenocarcinoma across Europe. Two trials are being conducted in Belgium and Spain, while one larger study is running across 15 European countries including Belgium, Spain, Austria, Bulgaria, Czechia, Denmark, Finland, France, Greece, Hungary, Italy, Netherlands, Poland, Portugal, and Romania.
The trials represent different approaches to treating advanced cancer. Two studies focus on antibody-drug conjugates (JK06 and JK08) that target specific proteins on cancer cells, while the third tests bemarituzumab, a targeted therapy for tumors with high levels of FGFR2b protein. Notably, the JK08 trial explores combination therapy using established medications like pembrolizumab and lenvatinib alongside the investigational drug.
All three trials are in early phases of research (Phase 1/2), focusing primarily on determining safety and optimal dosing before evaluating effectiveness. Patients interested in these trials should have already received at least one previous treatment, though specific requirements vary by study. The bemarituzumab study offers the widest geographic availability with locations across 15 countries, potentially providing more accessible options for European patients.
This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
